<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1141" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1141/" /><meta name="ncbi_pagename" content="Neuroferritinopathy - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Neuroferritinopathy - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Neuroferritinopathy" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2018/01/18" /><meta name="citation_author" content="Patrick F Chinnery" /><meta name="citation_pmid" content="20301320" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1141/" /><meta name="citation_keywords" content="Hereditary Ferritinopathy" /><meta name="citation_keywords" content="Hereditary Ferritinopathy" /><meta name="citation_keywords" content="Ferritin light chain" /><meta name="citation_keywords" content="FTL" /><meta name="citation_keywords" content="Neuroferritinopathy" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Neuroferritinopathy" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Patrick F Chinnery" /><meta name="DC.Date" content="2018/01/18" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1141/" /><meta name="description" content="Neuroferritinopathy typically presents with progressive adult-onset chorea or dystonia affecting one or two limbs, and subtle cognitive deficits. The movement disorder affects additional limbs within five to ten years and becomes more generalized within 20 years. When present, asymmetry remains throughout the course of the disorder. The majority of individuals develop a characteristic orofacial action-specific dystonia related to speech that leads to dysarthrophonia. Frontalis overactivity and orolingual dyskinesia are common. Cognitive deficits and behavioral issues become major problems with time." /><meta name="og:title" content="Neuroferritinopathy" /><meta name="og:type" content="book" /><meta name="og:description" content="Neuroferritinopathy typically presents with progressive adult-onset chorea or dystonia affecting one or two limbs, and subtle cognitive deficits. The movement disorder affects additional limbs within five to ten years and becomes more generalized within 20 years. When present, asymmetry remains throughout the course of the disorder. The majority of individuals develop a characteristic orofacial action-specific dystonia related to speech that leads to dysarthrophonia. Frontalis overactivity and orolingual dyskinesia are common. Cognitive deficits and behavioral issues become major problems with time." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1141/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/neuroferritin/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1141/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8C1108E0407D410000000001C800A5.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1141_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1141_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/nbia-ov/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/nf1/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1141_"><span class="title" itemprop="name">Neuroferritinopathy</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: Hereditary Ferritinopathy</div><p class="contrib-group"><span itemprop="author">Patrick F Chinnery</span>, BMedSci, MBBS, PhD, FRCPath, FRCP, FMedSci.</p><a data-jig="ncbitoggler" href="#__NBK1141_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1141_ai__"><div class="contrib half_rhythm"><span itemprop="author">Patrick F Chinnery</span>, BMedSci, MBBS, PhD, FRCPath, FRCP, FMedSci<div class="affiliation small">Department of Clinical Neurosciences<br />University of Cambridge<br />Cambridge, United Kingdom<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ku.ca.mac.lhcsdem@52cfp" class="oemail">ku.ca.mac.lhcsdem@52cfp</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">April 25, 2005</span>; Last Update: <span itemprop="dateModified">January 18, 2018</span>.</p><p><em>Estimated reading time: 15 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="neuroferritin.Summary" itemprop="description"><h2 id="_neuroferritin_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Neuroferritinopathy typically presents with progressive adult-onset chorea or dystonia affecting one or two limbs, and subtle cognitive deficits. The movement disorder affects additional limbs within five to ten years and becomes more generalized within 20 years. When present, asymmetry remains throughout the course of the disorder. The majority of individuals develop a characteristic orofacial action-specific dystonia related to speech that leads to dysarthrophonia. Frontalis overactivity and orolingual dyskinesia are common. Cognitive deficits and behavioral issues become major problems with time.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of neuroferritinopathy is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with typical clinical findings and/or identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>FTL</i> by molecular testing.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> While the movement disorder is particularly resistant to conventional therapy, some response has been recorded with levodopa, tetrabenazine, orphenadrine, benzhexol, sulpiride, diazepam, clonazepam, and deanol in standard doses; botulinum toxin may be helpful for painful focal dystonia.</p><p><i>Prevention of secondary complications:</i> Adequate caloric intake; physiotherapy to maintain mobility and prevent contractures.</p><p><i>Agents/circumstances to avoid:</i> Iron supplements are not recommended.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>Neuroferritinopathy is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner with 100% <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>. Most individuals diagnosed with neuroferritinopathy have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent; the proportion of cases caused by <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variants is unknown. Each child of an individual with neuroferritinopathy has a 50% chance of inheriting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Prenatal testing for pregnancies at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible if the <i>FTL</i> pathogenic variant in the family is known.</p></div></div><div id="neuroferritin.Diagnosis"><h2 id="_neuroferritin_Diagnosis_">Diagnosis</h2><div id="neuroferritin.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Neuroferritinopathy <b>should be suspected</b> in individuals with the following:</p><ul><li class="half_rhythm"><div>Adult-onset progressive movement disorder (either chorea or dystonia)</div></li><li class="half_rhythm"><div>Family history consistent with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> transmission</div></li><li class="half_rhythm"><div>Evidence of excess iron storage on brain MRI, and in advanced cases, cystic degeneration apparent on MRI (see <a class="figpopup" href="/books/NBK1141/figure/neuroferritin.F1/?report=objectonly" target="object" rid-figpopup="figneuroferritinF1" rid-ob="figobneuroferritinF1">Figure 1</a>)</div></li></ul><div class="iconblock whole_rhythm clearfix ten_col fig" id="figneuroferritinF1" co-legend-rid="figlgndneuroferritinF1"><a href="/books/NBK1141/figure/neuroferritin.F1/?report=objectonly" target="object" title="Figure 1" class="img_link icnblk_img figpopup" rid-figpopup="figneuroferritinF1" rid-ob="figobneuroferritinF1"><img class="small-thumb" src="/books/NBK1141/bin/neuroferritin-Image001.gif" src-large="/books/NBK1141/bin/neuroferritin-Image001.jpg" alt="Figure 1. a." /></a><div class="icnblk_cntnt" id="figlgndneuroferritinF1"><h4 id="neuroferritin.F1"><a href="/books/NBK1141/figure/neuroferritin.F1/?report=objectonly" target="object" rid-ob="figobneuroferritinF1">Figure 1</a></h4><p class="float-caption no_bottom_margin">a. Non-contrast brain CT symmetric low signal in the putamina b. T<sub>2</sub>-weighted MRI image showing cystic change involving the putamina and globus pallidi and with increased signal in the heads of the caudate nuclei [Crompton et al 2005]</p></div></div></div><div id="neuroferritin.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of neuroferritinopathy <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with typical clinical findings and/or identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>FTL</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1141/table/neuroferritin.T.molecular_genetic_testin/?report=objectonly" target="object" rid-figpopup="figneuroferritinTmoleculargenetictestin" rid-ob="figobneuroferritinTmoleculargenetictestin">Table 1</a>).</p><p>Molecular genetic testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, and <b>more comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>FTL</i> is performed first and followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</div><div class="half_rhythm">Note: Since neuroferritinopathy is thought to occur through a <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> mechanism and large intragenic <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> or <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> has not been reported, testing for intragenic deletions or duplication is unlikely to identify a disease-causing variant.</div><div class="half_rhythm">Targeted analysis for pathogenic variants can be performed first in individuals of United Kingdom (UK) ancestry.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>FTL</i> and other genes of interest (see <a href="#neuroferritin.Differential_Diagnosis">Differential Diagnosis</a>) may be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> and <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> may be considered. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> or genes that results in a similar clinical presentation). For an introduction to comprehensive genomic testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</div></li></ul><div id="neuroferritin.T.molecular_genetic_testin" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Neuroferritinopathy</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1141/table/neuroferritin.T.molecular_genetic_testin/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__neuroferritin.T.molecular_genetic_testin_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_neuroferritin.T.molecular_genetic_testin_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_neuroferritin.T.molecular_genetic_testin_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_neuroferritin.T.molecular_genetic_testin_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_neuroferritin.T.molecular_genetic_testin_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>FTL</i></td><td headers="hd_h_neuroferritin.T.molecular_genetic_testin_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_neuroferritin.T.molecular_genetic_testin_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td></tr><tr><td headers="hd_h_neuroferritin.T.molecular_genetic_testin_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>4</sup></td><td headers="hd_h_neuroferritin.T.molecular_genetic_testin_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None reported&#x000a0;<sup>5</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="neuroferritin.TF.1.1"><p class="no_margin">See <a href="/books/NBK1141/#neuroferritin.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="neuroferritin.TF.1.2"><p class="no_margin">See <a href="#neuroferritin.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="neuroferritin.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="neuroferritin.TF.1.4"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>5. </dt><dd><div id="neuroferritin.TF.1.5"><p class="no_margin">Neuroferritinopathy occurs through a <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> mechanism; therefore, large intragenic deletions or duplications are unlikely to cause disease.</p></div></dd></dl></div></div></div></div></div><div id="neuroferritin.Clinical_Characteristics"><h2 id="_neuroferritin_Clinical_Characteristics_">Clinical Characteristics</h2><div id="neuroferritin.Clinical_Description"><h3>Clinical Description</h3><p><b>Presentation and progression.</b> Neuroferritinopathy typically presents in adult life (mean age 40 years) [<a class="bk_pop" href="#neuroferritin.REF.chinnery.2007.110">Chinnery et al 2007</a>], although onset in early teenage years and in the sixth decade has been reported.</p><p>The two presenting phenotypes are typically chorea or dystonia affecting one or two limbs, although one individual presented with late-onset parkinsonism [<a class="bk_pop" href="#neuroferritin.REF.curtis.2001.350">Curtis et al 2001</a>, <a class="bk_pop" href="#neuroferritin.REF.burn.2006.176">Burn &#x00026; Chinnery 2006</a>, <a class="bk_pop" href="#neuroferritin.REF.chinnery.2007.110">Chinnery et al 2007</a>] and two families with cerebellar features [<a class="bk_pop" href="#neuroferritin.REF.vidal.2004.363">Vidal et al 2004</a>, <a class="bk_pop" href="#neuroferritin.REF.devos.2009.e109">Devos et al 2009</a>] (see <a class="figpopup" href="/books/NBK1141/table/neuroferritin.T.clinical_findings_in_ind/?report=objectonly" target="object" rid-figpopup="figneuroferritinTclinicalfindingsinind" rid-ob="figobneuroferritinTclinicalfindingsinind">Table 2</a>). Unusual presentations have also been described, related to an underlying dystonic gait [<a class="bk_pop" href="#neuroferritin.REF.keogh.2011.81">Keogh et al 2011</a>, <a class="bk_pop" href="#neuroferritin.REF.nishida.2014.173">Nishida et al 2014</a>].</p><p>The movement disorder is progressive, involving additional limbs in five to ten years and becoming more generalized within 20 years [<a class="bk_pop" href="#neuroferritin.REF.crompton.2005.95">Crompton et al 2005</a>].</p><ul><li class="half_rhythm"><div>Some individuals have striking asymmetry, which remains throughout the course of the disorder.</div></li><li class="half_rhythm"><div>The majority of individuals develop a characteristic orofacial action-specific dystonia related to speech and leading to dysarthrophonia.</div></li><li class="half_rhythm"><div>Frontalis overactivity is common, as is orolingual dyskinesia [<a class="bk_pop" href="#neuroferritin.REF.crompton.2005.95">Crompton et al 2005</a>].</div></li><li class="half_rhythm"><div>Eye movements are well preserved throughout the disease course.</div></li></ul><p>Subtle cognitive deficits are apparent in most individuals from the outset [<a class="bk_pop" href="#neuroferritin.REF.crompton.2005.95">Crompton et al 2005</a>]. Formal neuropsychometry reveals frontal/subcortical deficits [<a class="bk_pop" href="#neuroferritin.REF.wills.2002.91">Wills et al 2002</a>] that are not as prominent as those seen in <a href="/books/n/gene/huntington/">Huntington disease</a>. The cognitive and behavioral component eventually becomes a major problem.</p><div id="neuroferritin.T.clinical_findings_in_ind" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Clinical Findings in Individuals with Neuroferritinopathy</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1141/table/neuroferritin.T.clinical_findings_in_ind/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__neuroferritin.T.clinical_findings_in_ind_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_1" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:top;">Clinical Finding</th><th id="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Number</th><th id="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Percent</th></tr></thead><tbody><tr><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_1" rowspan="4" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Presenting</b><br /><b><a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a></b></td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Chorea</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">20/40</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">50%</td></tr><tr><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Dystonia</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">17/40</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">42.5%</td></tr><tr><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Parkinsonism</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3/40</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">7.5%</td></tr><tr><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Asymmetry of movement disorder</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">25/40</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">62.5%</td></tr><tr><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_1" rowspan="4" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Speech &#x00026;</b><br /><b>swallowing</b></td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dysarthria</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">31/40</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">77.5%</td></tr><tr><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Dysphonia</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">19/40</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">47.5%</td></tr><tr><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Orolingual dyskinesia</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">26/40</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">65%</td></tr><tr><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Dysphagia</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">16/40</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">40%</td></tr><tr><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Eyes</b></td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Abnormal EOM</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3/40</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">7.5%</td></tr><tr><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Abnormal fundi</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0/40</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0%</td></tr><tr><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_1" rowspan="9" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Motor</b></td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Bradykinesia</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">14/40</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">35.5%</td></tr><tr><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Tremor</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0/40</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0%</td></tr><tr><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Dystonia</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">33/40</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">82.5%</td></tr><tr><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Chorea</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">28/40</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">70%</td></tr><tr><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Spasticity</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0/40</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0%</td></tr><tr><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Normal strength in nondystonic limbs</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">40/40</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td></tr><tr><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Increased tendon reflexes</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">7/40</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">17.5%</td></tr><tr><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Babinski reflex</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0/40</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0%</td></tr><tr><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Ataxia</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0/40</td><td headers="hd_h_neuroferritin.T.clinical_findings_in_ind_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">In 40 individuals with the <i>FTL</i> c.460dupA <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#neuroferritin.REF.chinnery.2007.110">Chinnery et al 2007</a>]</p></div></dd><dt></dt><dd><div><p class="no_margin">EOM = extraocular muscle (function)</p></div></dd></dl></div></div></div><p><b>Neuroimaging.</b> From the outset, all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have evidence of excess brain iron accumulation on T<sub>2</sub><sup>*</sup>-weighted MRI. The iron deposition may be missed on other MR sequences in early stages of the disease. Later stages are associated with high signal on T<sub>2</sub>-weighted MRI in the caudate, globus pallidus, putamen, substantia nigra, and red nuclei, followed by cystic degeneration in the caudate and putamen. Neuroferritinopathy has a characteristic appearance, distinguishing it from other <a href="/books/n/gene/nbia-ov/">disorders associated with brain iron accumulation</a> [<a class="bk_pop" href="#neuroferritin.REF.mcneill.2008.1614">McNeill et al 2008</a>] and associated with progressive iron accumulation on MRI [<a class="bk_pop" href="#neuroferritin.REF.mcneill.2012.1810">McNeill et al 2012</a>], including the "eye of the tiger" sign [<a class="bk_pop" href="#neuroferritin.REF.mcneill.2012.1810">McNeill et al 2012</a>] and other radiologic features [<a class="bk_pop" href="#neuroferritin.REF.batla.2015.1816">Batla et la 2015</a>].</p><p><b>Histopathologic examination</b> of three individuals with the 460dupA <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> confirmed evidence of abnormal iron accumulation throughout the brain and particularly in the basal ganglia [<a class="bk_pop" href="#neuroferritin.REF.hautot.2007.21">Hautot et al 2007</a>]. Affected regions contain iron and ferritin-positive spherical inclusions, often co-localizing with microglia, oligodendrocytes, and neurons. Axonal swellings (neuroaxonal spheroids) that were immunoreactive to ubiquitin, tau, and neurofilaments were also present. <a class="bk_pop" href="#neuroferritin.REF.mancuso.2005.280">Mancuso et al [2005]</a> report similar neuropathologic findings in a person with <a class="figpopup" href="/books/NBK1141/table/neuroferritin.T.ftl_variants_discussed_i/?report=objectonly" target="object" rid-figpopup="figneuroferritinTftlvariantsdiscussedi" rid-ob="figobneuroferritinTftlvariantsdiscussedi">c.442dupC</a> in <i>FTL</i>.</p><p><b>Serum ferritin.</b> Serum ferritin concentrations were low (&#x0003c;20 &#x000b5;g/L) in the majority of males and postmenopausal females but within normal limits for premenopausal females [<a class="bk_pop" href="#neuroferritin.REF.chinnery.2007.110">Chinnery et al 2007</a>].</p></div><div id="neuroferritin.Penetrance"><h3>Penetrance</h3><p>Penetrance is 100% [<a class="bk_pop" href="#neuroferritin.REF.chinnery.2007.110">Chinnery et al 2007</a>].</p></div><div id="neuroferritin.Prevalence"><h3>Prevalence</h3><p>Prevalence is unknown. The majority of individuals described to date have the same <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>FTL</i>. Evidence suggests that they have descended from a common UK founder [<a class="bk_pop" href="#neuroferritin.REF.chinnery.2003.e69">Chinnery et al 2003</a>], although the identification of a person from the state of Texas with German ancestry raises the possibility of a recurrent 460dupA pathogenic variant [<a class="bk_pop" href="#neuroferritin.REF.ondo.2010.2470">Ondo et al 2010</a>].</p></div></div><div id="neuroferritin.Genetically_Related_Alleli"><h2 id="_neuroferritin_Genetically_Related_Alleli_">Genetically Related (Allelic) Disorders</h2><p>Heterozygous pathogenic variants in the iron-responsive element of <i>FTL</i>, located in the 5' UTR, have been identified in hereditary hyperferritinemia cataract syndrome (OMIM <a href="http://omim.org/entry/600886" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">600886</a>) in which an increase in the serum ferritin concentration is associated with bilateral cataracts developing in childhood or early adult life, but not with excess iron storage in the brain. Pathogenic variants in <i>FTL</i> causing neuroferritinopathy are found within the <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a>, and usually <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 4.</p></div><div id="neuroferritin.Differential_Diagnosis"><h2 id="_neuroferritin_Differential_Diagnosis_">Differential Diagnosis</h2><div id="neuroferritin.T.other_disorders_to_consi" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Other Disorders to Consider in the Differential Diagnosis of Neuroferritinopathy</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1141/table/neuroferritin.T.other_disorders_to_consi/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__neuroferritin.T.other_disorders_to_consi_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_1" style="text-align:left;vertical-align:middle;">Differential Diagnosis<br />Disorder</th><th id="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_2" style="text-align:left;vertical-align:middle;">Gene(s)</th><th id="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_3" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Clinical Features of the Differential Diagnosis Disorder</th></tr><tr><th headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_4" id="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Overlapping w/neuroferritinopathy</th><th headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_4" id="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distinguishing from neuroferritinopathy</th></tr></thead><tbody><tr><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/huntington/">Huntington disease</a></td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HTT</i></td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_4 hd_h_neuroferritin.T.other_disorders_to_consi_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Family history consistent w/AD inheritance</td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_4 hd_h_neuroferritin.T.other_disorders_to_consi_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Early neuropsychiatric features; brain imaging distinguishes diagnoses.</td></tr><tr><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/sca17/">Spinocerebellar ataxia type 17</a> (SCA17)</td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>TBP</i></td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_4 hd_h_neuroferritin.T.other_disorders_to_consi_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Family history consistent w/AD inheritance</td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_4 hd_h_neuroferritin.T.other_disorders_to_consi_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Spasticity (absent in neuroferritinopathy)</td></tr><tr><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/dystonia/">Early-onset primary dystonia</a> (DYT1)</td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>TOR1A</i>&#x000a0;<sup>1</sup></td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_4 hd_h_neuroferritin.T.other_disorders_to_consi_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Generalized dystonia</td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_4 hd_h_neuroferritin.T.other_disorders_to_consi_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Chorea uncommon; no psychiatric features</td></tr><tr><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/chac/">Chorea-acanthocytosis</a></td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>VPS13A</i></td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_4 hd_h_neuroferritin.T.other_disorders_to_consi_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Orofacial dyskinesia</td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_4 hd_h_neuroferritin.T.other_disorders_to_consi_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Impaired reflexes (preserved in neuroferritinopathy)</td></tr><tr><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/mcleod/">McLeod neuroacanthocytosis syndrome</a></td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>XK</i></td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XL</td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_4 hd_h_neuroferritin.T.other_disorders_to_consi_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Orofacial dyskinesia</td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_4 hd_h_neuroferritin.T.other_disorders_to_consi_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Absent deep tendon reflexes (preserved in neuroferritinopathy)</td></tr><tr><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/sca2/">SCA2</a></td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ATXN2</i></td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_4 hd_h_neuroferritin.T.other_disorders_to_consi_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dystonia</td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_4 hd_h_neuroferritin.T.other_disorders_to_consi_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ataxia &#x00026; neuropathy (a minor feature &#x00026; absent, respectively, in neuroferritinopathy)</td></tr><tr><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/sca3/">SCA3</a></td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ATXN3</i></td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_4 hd_h_neuroferritin.T.other_disorders_to_consi_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dystonia, chorea, orofacial movement disorder</td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_4 hd_h_neuroferritin.T.other_disorders_to_consi_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Spasticity (absent in neuroferritinopathy)</td></tr><tr><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/jpd/">Parkin-type of juvenile-onset Parkinson disease</a></td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PRKN</i></td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_4 hd_h_neuroferritin.T.other_disorders_to_consi_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Early-onset movement disorder</td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_4 hd_h_neuroferritin.T.other_disorders_to_consi_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Different MRI findings</td></tr><tr><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/acp/">Aceruloplasminemia</a></td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CP</i></td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_4 hd_h_neuroferritin.T.other_disorders_to_consi_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Early-onset movement disorder</td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_4 hd_h_neuroferritin.T.other_disorders_to_consi_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Different MRI findings</td></tr><tr><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/npc/">Neimann-Pick type C</a></td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>NPC1</i><br /><i>NPC2</i></td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_4 hd_h_neuroferritin.T.other_disorders_to_consi_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Early-onset movement disorder</td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_4 hd_h_neuroferritin.T.other_disorders_to_consi_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Different MRI findings</td></tr><tr><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/pkan/">Pantothenate kinase-associated neurodegeneration</a> (PKAN)</td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PANK2</i></td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_4 hd_h_neuroferritin.T.other_disorders_to_consi_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Very similar MRI findings incl "eye of the tiger" sign</td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_4 hd_h_neuroferritin.T.other_disorders_to_consi_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR inheritance; earlier onset</td></tr><tr><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mitochondrial disorders (see <a href="/books/n/gene/mt-overview/">Mitochondrial Disease Overview</a>)</td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Various</td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Various</td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_4 hd_h_neuroferritin.T.other_disorders_to_consi_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Basal ganglia abnormalities on MRI</td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_4 hd_h_neuroferritin.T.other_disorders_to_consi_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Different MRI findings</td></tr><tr><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/inad/">Infantile neuroaxonal dystrophy</a></td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PLA2G6</i></td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_4 hd_h_neuroferritin.T.other_disorders_to_consi_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Imaging findings resembling but distinct from neuroferritinopathy</td><td headers="hd_h_neuroferritin.T.other_disorders_to_consi_1_1_1_4 hd_h_neuroferritin.T.other_disorders_to_consi_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR inheritance; earlier onset</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>; XL = <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a></p></div></dd><dt>1. </dt><dd><div id="neuroferritin.TF.3.1"><p class="no_margin">Specifically the c.904_906delGAG (<a href="/nuccore/56550122" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000113<wbr style="display:inline-block"></wbr>​.2</a>) <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>TOR1A</i> [<a class="bk_pop" href="#neuroferritin.REF.crompton.2005.95">Crompton et al 2005</a>]</p></div></dd></dl></div></div></div><p>Neuroferritinopathy shares similar MRI appearances and clinical presentation of several other neurodegenerative disorders with brain iron accumulation (NBIA). However, the age of onset, inheritance pattern, and T<sub>2</sub>*-weighted MRI results can be used to distinguish these disorders [<a class="bk_pop" href="#neuroferritin.REF.mcneill.2008.1614">McNeill et al 2008</a>]. See <a href="/books/n/gene/nbia-ov/">Neurodegeneration with Brain Iron Accumulation Disorders Overview</a>.</p></div><div id="neuroferritin.Management"><h2 id="_neuroferritin_Management_">Management</h2><div id="neuroferritin.Evaluations_Following_Init"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease in an individual diagnosed with neuroferritinopathy, the following evaluations are recommended if they have not already been completed:</p><ul><li class="half_rhythm"><div>Psychometric assessment</div></li><li class="half_rhythm"><div>Physiotherapy evaluation</div></li><li class="half_rhythm"><div>Speech therapy assessment</div></li><li class="half_rhythm"><div>Dietary assessment because weight loss may develop in the late stages of the disorder</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="neuroferritin.Treatment_of_Manifestation"><h3>Treatment of Manifestations</h3><p>The movement disorder is particularly resistant to conventional therapy, but some response has been recorded with levodopa, tetrabenazine, orphenadrine, benzhexol, sulpiride, diazepam, clonazepam, and deanol in standard doses [<a class="bk_pop" href="#neuroferritin.REF.chinnery.2007.110">Chinnery et al 2007</a>, <a class="bk_pop" href="#neuroferritin.REF.ondo.2010.2470">Ondo et al 2010</a>]. However, no formal treatment trials have been carried out. Specific drugs are tried empirically based on the predominant symptoms. It is important to note that the predominant symptoms will change over time, requiring an adjustment of the medication. Such treatment is best managed by a clinician with expertise in movement disorders.</p><p>Botulinum toxin is helpful for painful focal dystonia.</p></div><div id="neuroferritin.Prevention_of_Secondary_Co"><h3>Prevention of Secondary Complications</h3><p>Dietary assessment is helpful; <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals should maintain caloric intake.</p><p>Physiotherapy helps to maintain mobility and prevent contractures.</p></div><div id="neuroferritin.AgentsCircumstances_to_Avo"><h3>Agents/Circumstances to Avoid</h3><p>Iron supplements are not recommended for <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals and those at risk. This recommendation is empiric [<a class="bk_pop" href="#neuroferritin.REF.chinnery.2007.110">Chinnery et al 2007</a>]. Iron replacement therapy with careful monitoring may be required if affected individuals develop coincidental iron deficiency anemia. There is no evidence to support avoidance of iron-rich foods by affected individuals [Author, personal observation].</p></div><div id="neuroferritin.Evaluation_of_Relatives_at"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#neuroferritin.Related_Genetic_Counseling">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="neuroferritin.Therapies_Under_Investigat"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="neuroferritin.Genetic_Counseling"><h2 id="_neuroferritin_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="neuroferritin.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Neuroferritinopathy is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p></div><div id="neuroferritin.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Most individuals diagnosed with neuroferritinopathy have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent.</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with neuroferritinopathy may have the disorder as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. The proportion of cases caused by <i>de novo</i> pathogenic variants is unknown.</div></li><li class="half_rhythm"><div>Recommendations for the evaluation of parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> include brain MRI, measurement of serum ferritin concentration, and <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> if the <i>FTL</i> pathogenic variant has been identified in the proband.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in leukocyte DNA of either parent, possible explanations include a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant in the proband or <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent. Though theoretically possible, no instances of germline mosaicism have been reported.</div></li><li class="half_rhythm"><div>The family history of some individuals diagnosed with neuroferritinopathy may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset of the disease in the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent. Therefore, an apparently negative family history cannot be confirmed unless <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> has been performed on the parents of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to the sibs of the proband depends on the genetic status of the proband's parents:</p><ul><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, the risk to the sibs is 50%.</div></li><li class="half_rhythm"><div>If the parents have been tested for the <i>FTL</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> and:</div><ul><li class="half_rhythm"><div>A parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has the <i>FTL</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the risk to the sibs of inheriting the variant is 50%. There may be differences in the age of onset and rate of progression, but the disorder has 100% <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>.</div></li><li class="half_rhythm"><div>The <i>FTL</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, the risk to sibs is presumed to be approximately 1% because of the theoretic possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul></li><li class="half_rhythm"><div>If the parents have not been tested for the <i>FTL</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> but are clinically unaffected, the risk to the sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> appears to be low. The sibs of a proband with clinically unaffected parents are still at increased risk for neuroferritinopathy because of the theoretic possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with neuroferritinopathy has a 50% chance of inheriting the <i>FTL</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. There may be differences in the age of onset and rate of progression of the disorder between members of the same family.</p><p><b>Other family members.</b> The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or has the <i>FTL</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members are at risk.</p></div><div id="neuroferritin.Related_Genetic_Counseling"><h3>Related Genetic Counseling Issues</h3><p><b>Testing of at-risk asymptomatic adults.</b> Testing of at-risk asymptomatic adult family members requires prior identification of the <i>FTL</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family. Such testing is not useful in accurately predicting age of onset, severity, type of symptoms, or rate of progression in asymptomatic individuals. When testing at-risk individuals for neuroferritinopathy, an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member should be tested first to confirm the molecular diagnosis in the family.</p><p>Testing for the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the absence of definite symptoms of the disease is predictive testing. At-risk asymptomatic adult family members may seek testing in order to make personal decisions regarding reproduction, financial matters, and career planning. Others may have different motivations including simply the "need to know." Testing of asymptomatic at-risk adult family members usually involves pre-test interviews in which the motives for requesting the test, the individual's knowledge of neuroferritinopathy, the possible impact of positive and negative test results, and neurologic status are assessed. Those seeking testing should be counseled regarding possible problems that they may encounter with regard to health, life, and disability insurance coverage, employment and educational discrimination, and changes in social and family interaction. Other issues to consider are implications for the at-risk status of other family members. Informed consent should be procured and records kept confidential. Individuals with a positive test result need arrangements for long-term follow up and evaluations.</p><p><b>Molecular genetic testing of asymptomatic children (in the US defined as individuals age &#x0003c;18 years)</b> who are at risk for adult-onset disorders for which no treatment exists is not considered appropriate, primarily because it negates the autonomy of the child with no compelling benefit. Further, concern exists regarding the potential unhealthy adverse effects that such information may have on family dynamics, the risk of discrimination and stigmatization in the future, and the anxiety that such information may cause.</p><p>In a family with an established diagnosis of neuroferritinopathy, genetic testing is always indicated in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or symptomatic individuals regardless of age.</p><p>For more information, see also the National Society of Genetic Counselors <a href="http://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">position statement</a> on genetic testing of minors for adult-onset conditions and the American Academy of Pediatrics and American College of Medical Genetics and Genomics <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">policy statement</a>: ethical and policy issues in genetic testing and screening of children.</p><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> condition has a pathogenic variant identified in the proband or clinical evidence of the disorder, it is likely that the proband has the disorder as a result of a <i>de novo</i> pathogenic variant. However, non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) and undisclosed adoption could also be explored.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="neuroferritin.Prenatal_Testing_and_Preim"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>FTL</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="neuroferritin.Resources"><h2 id="_neuroferritin_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>NBIA Disorders Association</b></div><div>2082 Monaco Court</div><div>El Cajon CA 92019-4235</div><div><b>Phone:</b> 619-588-2315</div><div><b>Fax:</b> 619-588-4093</div><div><b>Email:</b> info@NBIAdisorders.org</div><div><a href="https://www.nbiadisorders.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.nbiadisorders.org</a></div></li><li class="half_rhythm"><div><b>NBIA Disorders Association Research Registry and Treat Iron-Related Childhood-Onset Neurodegeneration (TIRCON) Registry</b></div><div> CA 92019-4235</div><div><b>Phone:</b> 619-588-2315</div><div><b>Fax:</b> 619-588-4093</div><div><b>Email:</b> pwood@nbiadisorders.org</div><div><a href="http://www.nbiadisorders.org/research/patient-registry?highlight=YToxOntpOjA7czo4OiJyZWdpc3RyeSI7fQ==" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">International Patient Registry &#x00026; Biomaterial Bank</a></div></li><li class="half_rhythm"><div><b>NBIAcure</b></div><div>Center of Excellence for NBIA Clinical Care and Research</div><div>International Registry for NBIA and Related Disorders</div><div>Oregon Health &#x00026; Science University</div><div><b>Phone:</b> 503-494-4344</div><div><b>Fax:</b> 503-494-6886</div><div><b>Email:</b> gregorya@ohsu.edu</div><div><a href="http://nbiacure.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.nbiacure.org</a></div></li></ul></div><div id="neuroferritin.Molecular_Genetics"><h2 id="_neuroferritin_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="neuroferritin.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Neuroferritinopathy: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1141/table/neuroferritin.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__neuroferritin.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_neuroferritin.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_neuroferritin.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_neuroferritin.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_neuroferritin.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_neuroferritin.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_neuroferritin.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_neuroferritin.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/2512" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>FTL</i></a></td><td headers="hd_b_neuroferritin.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=2512" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">19q13<wbr style="display:inline-block"></wbr>​.33</a></td><td headers="hd_b_neuroferritin.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P02792" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Ferritin light chain</a></td><td headers="hd_b_neuroferritin.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/FTL" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FTL database</a></td><td headers="hd_b_neuroferritin.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=FTL" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FTL</a></td><td headers="hd_b_neuroferritin.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=FTL[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FTL</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="neuroferritin.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="neuroferritin.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Neuroferritinopathy (<a href="/omim/134790,606159" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1141/table/neuroferritin.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__neuroferritin.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/134790" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">134790</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FERRITIN LIGHT CHAIN; FTL</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/606159" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">606159</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 3; NBIA3</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>FTL</i> has four exons. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1141/#neuroferritin.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Approximately ten pathogenic variants in <i>FTL</i> have been associated with neuroferritinopathy. The common c.460dupA <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 4 was observed in 10/12 families (~80%) [<a class="bk_pop" href="#neuroferritin.REF.curtis.2001.350">Curtis et al 2001</a>, <a class="bk_pop" href="#neuroferritin.REF.chinnery.2007.110">Chinnery et al 2007</a>]. The majority of pathogenic variants lie in exon 4. A single pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant (c.474G&#x0003e;A) has been described (see <a class="figpopup" href="/books/NBK1141/table/neuroferritin.T.ftl_variants_discussed_i/?report=objectonly" target="object" rid-figpopup="figneuroferritinTftlvariantsdiscussedi" rid-ob="figobneuroferritinTftlvariantsdiscussedi">Table 4</a>) [<a class="bk_pop" href="#neuroferritin.REF.curtis.2001.350">Curtis et al 2001</a>, <a class="bk_pop" href="#neuroferritin.REF.vidal.2004.363">Vidal et al 2004</a>, <a class="bk_pop" href="#neuroferritin.REF.maciel.2005.603">Maciel et al 2005</a>, <a class="bk_pop" href="#neuroferritin.REF.mancuso.2005.280">Mancuso et al 2005</a>, <a class="bk_pop" href="#neuroferritin.REF.devos.2009.e109">Devos et al 2009</a>, <a class="bk_pop" href="#neuroferritin.REF.kubota.2009.441">Kubota et al 2009</a>, <a class="bk_pop" href="#neuroferritin.REF.moutton.2014.935">Moutton et al 2014</a>].</p><div id="neuroferritin.T.ftl_variants_discussed_i" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p><i>FTL</i> Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1141/table/neuroferritin.T.ftl_variants_discussed_i/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__neuroferritin.T.ftl_variants_discussed_i_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_neuroferritin.T.ftl_variants_discussed_i_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_neuroferritin.T.ftl_variants_discussed_i_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_neuroferritin.T.ftl_variants_discussed_i_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_neuroferritin.T.ftl_variants_discussed_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.439_442dupGACC</td><td headers="hd_h_neuroferritin.T.ftl_variants_discussed_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.His148ArgfsTer34</td><td headers="hd_h_neuroferritin.T.ftl_variants_discussed_i_1_1_1_3" rowspan="7" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nucleotide/56682960" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000146<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/protein/20149498" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000137<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_neuroferritin.T.ftl_variants_discussed_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.442dupC<br />(646_647insC)</td><td headers="hd_h_neuroferritin.T.ftl_variants_discussed_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.His148ProfsTer33</td></tr><tr><td headers="hd_h_neuroferritin.T.ftl_variants_discussed_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.458dupA</td><td headers="hd_h_neuroferritin.T.ftl_variants_discussed_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.His153GlnfsTer28</td></tr><tr><td headers="hd_h_neuroferritin.T.ftl_variants_discussed_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.460dupA<br />(460_461insA)</td><td headers="hd_h_neuroferritin.T.ftl_variants_discussed_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg154LysfsTer27</td></tr><tr><td headers="hd_h_neuroferritin.T.ftl_variants_discussed_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.469_484dup16</td><td headers="hd_h_neuroferritin.T.ftl_variants_discussed_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Leu162ArgfsTer24</td></tr><tr><td headers="hd_h_neuroferritin.T.ftl_variants_discussed_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.474G&#x0003e;A</td><td headers="hd_h_neuroferritin.T.ftl_variants_discussed_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala96Thr</td></tr><tr><td headers="hd_h_neuroferritin.T.ftl_variants_discussed_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.498_499dupCT<br />(498insTC)</td><td headers="hd_h_neuroferritin.T.ftl_variants_discussed_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Phe167SerfsTer26</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the author. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="neuroferritin.TF.4.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Ferritin has two main subunits, H and L, and is involved in the storage and detoxification of iron. A functional ferritin molecule can store up to 4,500 iron molecules. The proportion of H and L subunits varies among tissues.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The c.460dupA variant is predicted to alter 22 C-terminal residues (the D-helix, the DE loop, and the E-helix) of the ferritin molecule, extending the protein by four amino acids. The extension is predicted to alter its iron storage capacity, possibly leading to an excessive release of toxic iron within neurons through a <a class="def" href="/books/n/gene/glossary/def-item/dominant-negative/">dominant-negative</a> effect; mitochondrial respiratory chain function may also be involved, as abnormal mitochondrial respiratory function has been documented in numerous individuals with neuroferritinopathy.</p></div><div id="neuroferritin.References"><h2 id="_neuroferritin_References_">References</h2><div id="neuroferritin.Published_Guidelines__Cons"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="neuroferritin.REF1">Committee on Bioethics, Committee on Genetics, and American College of Medical Genetics and Genomics Social, Ethical, Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Available <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2013. Accessed 10-29-19. [<a href="/pubmed/23428972" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23428972</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="neuroferritin.REF2">National Society of Genetic Counselors. Position statement on genetic testing of minors for adult-onset disorders. Available <a href="http://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2018. Accessed 10-29-19.</div></li></ul></div><div id="neuroferritin.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="neuroferritin.REF.batla.2015.1816">Batla A, Adams ME, Erro R, Ganos C, Balint B, Mencacci NE, Bhatia KP. Cortical pencil lining in neuroferritinopathy: a diagnostic clue. <span><span class="ref-journal">Neurology. </span>2015;<span class="ref-vol">84</span>:1816–8.</span> [<a href="/pmc/articles/PMC4424124/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4424124</span></a>] [<a href="/pubmed/25832658" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25832658</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="neuroferritin.REF.burn.2006.176">Burn J, Chinnery PF. Neuroferritinopathy. <span><span class="ref-journal">Semin Pediatr Neurol. </span>2006;<span class="ref-vol">13</span>:176–81.</span> [<a href="/pubmed/17101456" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17101456</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="neuroferritin.REF.chinnery.2007.110">Chinnery PF, Crompton DE, Birchall D, Jackson MJ, Coulthard A, Lombes A, Quinn N, Wills A, Fletcher N, Mottershead JP, Cooper P, Kellett M, Bates D, Burn J. Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. <span><span class="ref-journal">Brain. </span>2007;<span class="ref-vol">130</span>:110–9.</span> [<a href="/pubmed/17142829" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17142829</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="neuroferritin.REF.chinnery.2003.e69">Chinnery PF, Curtis AR, Fey C, Coulthard A, Crompton D, Curtis A, Lombes A, Burn J. Neuroferritinopathy in a French family with late onset dominant dystonia. <span><span class="ref-journal">J Med Genet. </span>2003;<span class="ref-vol">40</span>:e69.</span> [<a href="/pmc/articles/PMC1735466/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735466</span></a>] [<a href="/pubmed/12746423" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12746423</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="neuroferritin.REF.crompton.2005.95">Crompton DE, Chinnery PF, Bates D, Walls TJ, Jackson MJ, Curtis AJ, Burn J. Spectrum of movement disorders in neuroferritinopathy. <span><span class="ref-journal">Mov Disord. </span>2005;<span class="ref-vol">20</span>:95–9.</span> [<a href="/pubmed/15390132" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15390132</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="neuroferritin.REF.curtis.2001.350">Curtis AR, Fey C, Morris CM, Bindoff LA, Ince PG, Chinnery PF, Coulthard A, Jackson MJ, Jackson AP, McHale DP, Hay D, Barker WA, Markham AF, Bates D, Curtis A, Burn J. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. <span><span class="ref-journal">Nat Genet. </span>2001;<span class="ref-vol">28</span>:350–4.</span> [<a href="/pubmed/11438811" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11438811</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="neuroferritin.REF.devos.2009.e109">Devos D, Tchofo PJ, Vuillaume I, Dest&#x000e9;e A, Batey S, Burn J, Chinnery PF. Clinical features and natural history of neuroferritinopathy caused by the 458dupA FTL mutation. <span><span class="ref-journal">Brain. </span>2009;<span class="ref-vol">132</span>:e109.</span> [<a href="/pmc/articles/PMC2685918/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2685918</span></a>] [<a href="/pubmed/18854324" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18854324</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="neuroferritin.REF.hautot.2007.21">Hautot D, Pankhurst QA, Morris CM, Curtis A, Burn J, Dobson J. Preliminary observation of elevated levels of nanocrystalline iron oxide in the basal ganglia of neuroferritinopathy patients. <span><span class="ref-journal">Biochim Biophys Acta. </span>2007;<span class="ref-vol">1772</span>:21–5.</span> [<a href="/pmc/articles/PMC1993816/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1993816</span></a>] [<a href="/pubmed/17097860" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17097860</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="neuroferritin.REF.keogh.2011.81">Keogh MJ, Khan A, Gorman G, McNeill A, Horvath R, Burn J, Chinnery PF. An unusual gait following the discovery of a new disease. <span><span class="ref-journal">Pract Neurol. </span>2011;<span class="ref-vol">11</span>:81–4.</span> [<a href="/pubmed/21385964" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21385964</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="neuroferritin.REF.kubota.2009.441">Kubota A, Hida A, Ichikawa Y, Momose Y, Goto J, Igeta Y, Hashida H, Yoshida K, Ikeda S, Kanazawa I, Tsuji S. A novel ferritin light chain gene mutation in a Japanese family with neuroferritinopathy: description of clinical features and implications for genotype-phenotype correlations. <span><span class="ref-journal">Mov Disord. </span>2009;<span class="ref-vol">24</span>:441–5.</span> [<a href="/pubmed/19117339" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19117339</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="neuroferritin.REF.maciel.2005.603">Maciel P, Cruz VT, Constante M, Iniesta I, Costa MC, Gallati S, Sousa N, Sequeiros J, Coutinho P, Santos MM. Neuroferritinopathy: missense mutation in FTL causing early-onset bilateral pallidal involvement. <span><span class="ref-journal">Neurology. </span>2005;<span class="ref-vol">65</span>:603–5.</span> [<a href="/pmc/articles/PMC2886026/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2886026</span></a>] [<a href="/pubmed/16116125" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16116125</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="neuroferritin.REF.mancuso.2005.280">Mancuso M, Davidzon G, Kurlan RM, Tawil R, Bonilla E, Di Mauro S, Powers JM. Hereditary ferritinopathy: a novel mutation, its cellular pathology, and pathogenetic insights. <span><span class="ref-journal">J Neuropathol Exp Neurol. </span>2005;<span class="ref-vol">64</span>:280–94.</span> [<a href="/pubmed/15835264" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15835264</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="neuroferritin.REF.mcneill.2008.1614">McNeill A, Birchall D, Hayflick SJ, Gregory A, Schenk JF, Zimmerman EA, Shang H, Miyajima H, Chinnery PF. T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation. <span><span class="ref-journal">Neurology. </span>2008;<span class="ref-vol">70</span>:1614–9.</span> [<a href="/pmc/articles/PMC2706154/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2706154</span></a>] [<a href="/pubmed/18443312" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18443312</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="neuroferritin.REF.mcneill.2012.1810">McNeill A, Gorman G, Khan A, Horvath R, Blamire AM, Chinnery PF. Progressive brain iron accumulation in neuroferritinopathy measured by the thalamic T2* relaxation rate. <span><span class="ref-journal">AJNR Am J Neuroradiol. </span>2012;<span class="ref-vol">33</span>:1810–3.</span> [<a href="/pmc/articles/PMC4038493/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4038493</span></a>] [<a href="/pubmed/22499840" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22499840</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="neuroferritin.REF.moutton.2014.935">Moutton S, Fergelot P, Trocello JM, Plante-Bordeneuve V, Houcinat N, Wenisch E, Larue V, Brugi&#x000e8;res P, Clot F, Lacombe D, Arveiler B, Goizet C. A novel FTL mutation responsible for neuroferritinopathy with asymmetric clinical features and brain anomalies. <span><span class="ref-journal">Parkinsonism Relat Disord. </span>2014;<span class="ref-vol">20</span>:935–7.</span> [<a href="/pubmed/24907184" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24907184</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="neuroferritin.REF.nishida.2014.173">Nishida K, Garringer HJ, Futamura N, Funakawa I, Jinnai K, Vidal R, Takao M. A novel ferritin light chain mutation in neuroferritinopathy with an atypical presentation. <span><span class="ref-journal">J Neurol Sci. </span>2014;<span class="ref-vol">342</span>:173–7.</span> [<a href="/pmc/articles/PMC4048789/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4048789</span></a>] [<a href="/pubmed/24825732" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24825732</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="neuroferritin.REF.ondo.2010.2470">Ondo WG, Adam OR, Jankovic J, Chinnery PF. Dramatic response of facial stereotype/tic to tetrabenazine in the first reported cases of neuroferritinopathy in the United States. <span><span class="ref-journal">Mov Disord. </span>2010;<span class="ref-vol">25</span>:2470–2.</span> [<a href="/pubmed/20818611" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20818611</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="neuroferritin.REF.vidal.2004.363">Vidal R, Ghetti B, Takao M, Brefel-Courbon C, Uro-Coste E, Glazier BS, Siani V, Benson MD, Calvas P, Miravalle L, Rascol O, Delisle MB. Intracellular ferritin accumulation in neural and extraneural tissue characterizes a neurodegenerative disease associated with a mutation in the ferritin light polypeptide gene. <span><span class="ref-journal">J Neuropathol Exp Neurol. </span>2004;<span class="ref-vol">63</span>:363–80.</span> [<a href="/pubmed/15099026" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15099026</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="neuroferritin.REF.wills.2002.91">Wills AJ, Sawle GV, Guilbert PR, Curtis AR. Palatal tremor and cognitive decline in neuroferritinopathy. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>2002;<span class="ref-vol">73</span>:91–2.</span> [<a href="/pmc/articles/PMC1757327/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1757327</span></a>] [<a href="/pubmed/12082064" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12082064</span></a>]</div></li></ul></div></div><div id="neuroferritin.Chapter_Notes"><h2 id="_neuroferritin_Chapter_Notes_">Chapter Notes</h2><div id="neuroferritin.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>18 January 2018 (ha) Comprehensive update posted live</div></li><li class="half_rhythm"><div>23 December 2010 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>8 August 2007 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>30 November 2006 (pfc) Revision: <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> clinically available; addition of relevant material from author's new paper, Chinnery et al 2007</div></li><li class="half_rhythm"><div>25 April 2005 (me) Review posted live</div></li><li class="half_rhythm"><div>1 September 2004 (pfc) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1141</span><span class="label">PMID: <a href="/pubmed/20301320" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301320</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/nbia-ov/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/nf1/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1141&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1141/?report=reader">PubReader</a></li><li><a href="/books/NBK1141/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1141" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1141" style="display:none" title="Cite this Page"><div class="bk_tt">Chinnery PF. Neuroferritinopathy. 2005 Apr 25 [Updated 2018 Jan 18]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1141/pdf/Bookshelf_NBK1141.pdf">PDF version of this page</a> (511K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#neuroferritin.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#neuroferritin.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#neuroferritin.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#neuroferritin.Genetically_Related_Alleli" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#neuroferritin.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#neuroferritin.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#neuroferritin.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#neuroferritin.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#neuroferritin.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#neuroferritin.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#neuroferritin.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2512[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">FTL</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1495946" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1495946" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1495946" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1495946" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301681" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Furukawa Y. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301294" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ATP1A3-</i>Related Neurologic Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ATP1A3-</i>Related Neurologic Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Brashear A, Sweadner KJ, Cook JF, Swoboda KJ, Ozelius L. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/30605297" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> DYT-GNAL</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> DYT-GNAL<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Deutschländer AB, Wszolek ZK. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28749637" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">SLC6A3</i>-Related Dopamine Transporter Deficiency Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">SLC6A3</i>-Related Dopamine Transporter Deficiency Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Kurian MA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/29697234" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">KMT2B</i>-Related Dystonia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">KMT2B</i>-Related Dystonia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Abela L, Kurian MA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301320" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301320" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e040c0f39a66ee2ba430ce6">Neuroferritinopathy - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Neuroferritinopathy - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:25:35-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal105&amp;ncbi_phid=CE8C1108E0407D410000000001C800A5&amp;ncbi_session=CE8C1108E040C0F1_0456SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1141%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1141&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1141/&amp;ncbi_pagename=Neuroferritinopathy - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8C1108E040C0F1_0456SID /projects/books/PBooks@5.22 portal105 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>